The following is a partial transcript of Ricks’ speech to the Economic Club of Indiana on April 20, in which he spoke about problems in Indiana’s business climate.
While discussions about opportunities for improvement are important, they should also be framed in context of relative strengths. Indiana is strong and getting stronger.
Eli Lilly and Co. posted profit of $1.9 billion in the first quarter, up 40%, on higher sales of COVID-19 antibodies and other key products for diabetes, cancer and arthritis.
The drug, called tirzepatide, has been closely watched by medical professionals and is viewed by financial analysts as possible blockbuster, with potential annual sales in the billions of dollars.
The imaging agent is the six-year-old company’s first commercial launch, following millions of dollars’ worth of research and clinical tests. It was approved by the U.S. Food and Drug Administration in December.
When it comes to competing for jobs, Indiana is far behind the curve in critical ways, Eli Lilly and Co. CEO David Ricks told a lunch crowd Wednesday at the Economic Club of Indiana.
Acacia Pharma Group employees are waiting to see what will happen to their jobs and whether the company will remain in Indianapolis in any form, now that it is being acquired by New Jersey-based specialty drugmaker Eagle Pharmaceuticals Inc. for $103.9 million.
CEO Jeff Simmons’ goal is to make Indianapolis “an epicenter of animal health innovation.” While a bold goal, Simmons has proven he is a bold leader who prioritizes the growth of his company, as well as the community.
The push by Eli Lilly and Co. will come despite an unfavorable ruling last week from Medicare that sharply restricts reimbursements for a drug in the same class.
Local officials and not-for-profits are exploring the potential sale of carbon credits to finance the maintenance and preservation of city parks, and to purchase land for more.
Former Indiana University Health executive Ryan Kitchell will replace former chair and Indiana Higher Education Commissioner Teresa Lubbers, who announced she would step down from both roles in November.
The proposal would require disclosure of risks climate change pose to companies and the amount of greenhouse gas emissions produced by companies and by their supply chain.
The Affordable Insulin Now Act will serve as a political vehicle to rally Democrats and force Republicans who oppose it into uncomfortable votes ahead of the midterms.
An unnamed Cummins shareholder is proposing that the company separate its CEO and board chair roles, which are both held by Tom Linebarger. Cummins is recommending that shareholders vote against this proposal.
